← Back to Screener
Matinas BioPharma Holdings, Inc. (MTNB)
Price$0.55
Favorite Metrics
Price vs S&P 500 (26W)-76.97%
Price vs S&P 500 (4W)-22.36%
Market Capitalization$3.52M
All Metrics
Book Value / Share (Quarterly)$0.75
P/TBV (Annual)1.46x
Cash Flow / Share (Quarterly)$-1.09
Price vs S&P 500 (YTD)-10.24%
Net Profit Margin (TTM)-479.27%
EPS (TTM)$-1.62
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-1.62
EPS (Annual)$-4.98
ROI (Annual)-318.80%
Net Profit Margin (5Y Avg)-21226.03%
Cash / Share (Quarterly)$0.62
ROA (Last FY)-191.84%
EBITD / Share (TTM)$-1.55
ROE (5Y Avg)-115.12%
Operating Margin (TTM)-483.12%
Cash Flow / Share (Annual)$-1.09
P/B Ratio0.73x
P/B Ratio (Quarterly)0.78x
Net Income / Employee (Annual)$-8
EV / Revenue (TTM)-0.11x
Net Interest Coverage (TTM)-459.25x
ROA (TTM)-92.02%
EPS Incl Extra (Annual)$-4.98
Current Ratio (Annual)2.79x
Quick Ratio (Quarterly)2.77x
3-Month Avg Trading Volume0.03M
52-Week Price Return-8.50%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.40
P/S Ratio (Annual)3.21x
Asset Turnover (Annual)0.04x
52-Week High$3.09
Operating Margin (5Y Avg)-21513.86%
EPS Excl Extra (Annual)$-4.98
Tangible BV CAGR (5Y)-46.87%
26-Week Price Return-70.08%
Quick Ratio (Annual)2.77x
13-Week Price Return-21.57%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.79x
Enterprise Value$-0.475
Asset Turnover (TTM)0.09x
Book Value / Share Growth (5Y)18.81%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2093.25%
Cash / Share (Annual)$0.62
3-Month Return Std Dev86.27%
Net Income / Employee (TTM)$-3
ROE (Last FY)-319.51%
EPS Basic Excl Extra (Annual)$-4.98
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.62
ROI (TTM)-137.17%
P/S Ratio (TTM)0.82x
Pretax Margin (5Y Avg)-21226.03%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.40
Price vs S&P 500 (52W)-43.13%
Year-to-Date Return-6.31%
5-Day Price Return3.78%
EPS Normalized (Annual)$-4.98
ROA (5Y Avg)-79.94%
Net Profit Margin (Annual)-2093.25%
Month-to-Date Return9.80%
Cash Flow / Share (TTM)$-0.10
EBITD / Share (Annual)$-4.92
Operating Margin (Annual)-2124.27%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-114.93%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.62
P/TBV (Quarterly)1.46x
P/B Ratio (Annual)0.78x
Pretax Margin (TTM)-479.27%
Book Value / Share (Annual)$0.75
Price vs S&P 500 (13W)-23.95%
Beta1.47x
Revenue / Share (TTM)$0.00
ROE (TTM)-137.45%
52-Week Low$0.48
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
2.29
2.29
2.29
2.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MTNBMatinas BioPharma Holdings, Inc. | 0.82x | — | — | — | $0.55 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Matinas BioPharma is a clinical-stage biopharmaceutical company developing novel pharmaceutical treatments. The company's pipeline includes MAT2203, MAT2501, and other therapeutic candidates. The company focuses on identifying and advancing innovative drug candidates through clinical development.